Suchergebnisse - "Powles, T"

PubPharm (507)

31

CSN1 somatic mutations in penile squamous cell carcinoma

enthalten in: Cancer research | 2016

von Feber, A. | Worth, D. | Chakravarthy, A. | +17

32

Where next in kidney cancer?

enthalten in: Annals of oncology | 2016

von Powles, T.

33

Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC)

enthalten in: European urology / Supplements | 2016

von Powles, T. | Motzer, R. | Escudier, B. | +4

34

A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)

enthalten in: Annals of oncology | 2016

von Powles, T. | Grivas, P. | Aragon-Ching, J. | +7

35

Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)

enthalten in: Annals of oncology | 2016

von Cella, D. | Escudier, B. | Tannir, N. | +17

36

Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database

enthalten in: Annals of oncology | 2016

von Bamias, A. | Tzannis, K. | Liontos, M. | +16

37

Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: a retrospective chart review in the EU

enthalten in: Annals of oncology | 2016

von Heng, D. | Park, J. | Signorovitch, J. | +5

38

285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)

enthalten in: Annals of oncology | 2016

von Park, S. | Castellano, D. | Petrylak, D. | +11

39

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials : results of the DATECAN project†

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Kramar, A. | Negrier, S. | Sylvester, R. | +82

40

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair

enthalten in: Oncogene | 2015

von Kanu, N. | Grönroos, E. | Martinez, P. | +26

CommentIn: Nat Rev Urol. 2015 Apr;12(4):183. - PMID 25782172